目的:CCL20是一种参与免疫细胞募集和癌症进展的趋化因子。然而,CCL20在乳腺癌预后中的作用尚不清楚.本研究分析了CCL20表达与免疫浸润的相关性。临床病理参数,乳腺癌患者的预后。
方法:CCL20表达与临床病理参数的相关性,预后,乳腺癌的免疫浸润是使用TIMER来确定的,UALCAN,和PrognoScan数据库。此外,使用GeneMANIA和STING网络构建确定基因-基因和蛋白质-蛋白质相互作用,分别。
结果:CCL20表达在乳腺癌中显著上调,并与临床病理特征显著相关,包括种族,性别,年龄,更年期状态,癌症阶段,癌症亚类,和淋巴结转移;此外,CCL20表达较高的患者预后较差.同时,CCL20的表达与乳腺癌中免疫细胞的浸润密切相关。包括单核细胞,中性粒细胞,肿瘤相关巨噬细胞,Th1细胞,调节性T细胞,和耗尽的T细胞。此外,CCL20表达网络显示大多数基因和蛋白与免疫反应相关。
结论:CCL20与免疫浸润水平相关,是乳腺癌预后相关的生物标志物,也有可能成为治疗靶点。
OBJECTIVE: CCL20 is a chemotactic factor that is involved in immune cell recruitment and cancer progression. However, the role of
CCL20 in the prognosis of breast cancer remains unclear. This study analyzed correlations between
CCL20 expression and immune infiltration, clinicopathological parameters, and prognosis in breast cancer patients.
METHODS: Correlations between
CCL20 expression and clinicopathological parameters, prognosis, and immune infiltration in breast cancer were determined using the TIMER, UALCAN, and PrognoScan databases. Furthermore, gene-gene and protein-protein interactions were determined using GeneMANIA and STING network construction, respectively.
RESULTS: CCL20 expression was significantly upregulated in breast cancer and had significant associations with clinicopathological features, including race, sex, age, menopause status, cancer stage, cancer subclass, and nodal metastasis; moreover, patients with higher CCL20 expression exhibited poor prognosis. Meanwhile, CCL20 expression was significantly correlated with the infiltration of immune cells in breast cancer, including monocytes, neutrophils, tumor-associated macrophages, Th1 cells, regulatory T cells, and exhausted T cells. Moreover, the network of CCL20 expression showed the majority genes and proteins were associated with immune reactions.
CONCLUSIONS: CCL20 is a prognosis-related biomarker in breast cancer on the basis of its correlation with immune infiltration levels and has potential to also be a therapeutic target.